AUS
NZ
UK
CA
USA
IND
AFT Pharmaceuticals Limited announced FY26 total sales of $254.7 million, marking a 22 percent increase year-over-year as the New Zealand-based pharmaceutical firm accelerates its global expansion across 87 countries. Known for developing and licensing innovative treatments including its flagship Maxigesic product, AFT achieved a record operating profit of $24.4 million and boosted its dividend by 39 percent to 2.5 cents per share. With products now available in 87 countries and a robust pipeline featuring 8 patented products, the company aims to reach $300 million in annual revenue by expanding strategically in Europe, North America, Asia, and Africa.
Key Points
- AFT Pharmaceuticals Limited (AFP) recorded FY26 sales of $254.7 million, reflecting 22 percent year-on-year growth and a 17.6 percent compound annual growth rate over 22 years
- The company posted a record operating profit of $24.4 million in FY26 and increased its dividend to 2.5 cents per share, a 39 percent rise from the previous year
- AFT’s products are distributed in 87 countries globally, supported by agreements in over 100 countries, with ongoing expansion efforts in Europe, North America, Asia, and Africa
- The active research and development pipeline includes 8 patented products, 7 programmes in commercialisation, and over 24 off-patent injectable formulations under development
- Australian revenue reached $151 million in FY26, growing at a 17.2 percent compound annual rate, while Asian revenue surged to $16 million with a 51.6 percent compound annual growth rate over 11 years
- AFT executed 9 licensing agreements in FY26 and operates through direct distribution in key markets and via licensees and distributors internationally
More Than Two Decades of Continuous Growth and Sustained Profitability
Since its founding over 25 years ago by Dr Hartley and Marree Atkinson, AFT Pharmaceuticals has maintained uninterrupted revenue growth from FY05 through FY26. Revenue expanded from $8.4 million in FY05 to $254.7 million in FY26, representing a 17.6 percent compound annual growth rate over 22 years. This steady growth underscores AFT’s disciplined strategy of addressing unmet clinical needs through development and licensing of intellectual property to improve global patient outcomes.
Following a $33 million IPO in 2015 aimed at funding aggressive research and development for Maxigesic and other proprietary products, AFT returned to profitability in FY19. The company has since sustained profitable growth, posting a $24.4 million operating profit in FY26, while continuing to expand its global footprint and commercialise new products. The financial results demonstrate effective deployment of IPO capital to generate near-term profits and long-term growth across multiple regions and therapeutic areas.
Record Operating Profit and Increased Dividends in FY26
AFT Pharmaceuticals achieved a record operating profit of $24.4 million in FY26, highlighting strong operational performance and growing contributions from established and newly launched products. This milestone reflects the company’s transition from post-IPO investment to a mature, profitable business model. Despite ongoing significant R&D investments, core pharmaceutical sales and distribution generate sufficient cash flow to support shareholder returns and continued innovation.
The dividend was raised to 2.5 cents per share in FY26, a 39 percent increase over the prior year, signaling management’s confidence in sustained profitability and cash flow generation. Combined with 22 percent revenue growth and record profits, the enhanced dividend underscores AFT’s capacity to reward investors while investing in product development and international expansion.
Strong Growth in Asian Markets with 51.6 Percent CAGR
AFT’s Asian markets have experienced exceptional growth, with revenue rising at a 51.6 percent compound annual growth rate over 11 years, compared to 17.2 percent in the more mature Australian market. Asian revenue reached $16 million in FY26, up from $1 million in FY15. This growth is driven by strategic investments in direct distribution and partnerships with local distributors in key markets such as Singapore, Hong Kong, Malaysia, and China, with further expansion opportunities in Japan and China.
The company’s Asian strategy combines direct distribution via subsidiaries and collaborations with local licensees and distributors, enabling effective navigation of diverse regulatory environments while maintaining brand and IP control. This approach has successfully expanded AFT’s presence across multiple Asian countries, with significant potential for further growth, especially in the underpenetrated Chinese pharmaceutical market.
Australia Remains Core Market with $151 Million in FY26 Revenue
Australia continues to be AFT Pharmaceuticals’ largest market, generating $151 million in FY26, accounting for approximately 59 percent of total group sales. The Australian business has sustained a 17.2 percent compound annual growth rate over 11 years, reflecting strong demand and market share growth in a competitive pharmaceutical environment. This market provides a stable and profitable base supporting AFT’s international expansion and R&D investments.
Direct distribution operations and a large commercial team in Australia manage relationships with pharmacies, retailers, healthcare providers, and other channels. Success in Australia is anchored by the flagship Maxigesic product and other offerings in both over-the-counter and prescription segments. Consistent growth amid regulatory and competitive pressures highlights the strength of AFT’s brand portfolio and operational capabilities.
Global Distribution Network Covers 87 Countries with Over 100 Partnerships
AFT Pharmaceuticals’ products are now available in 87 countries worldwide, supported by distribution agreements in more than 100 countries, a significant expansion from just 3 countries in FY15. This global footprint is achieved through direct operations in key developed markets and partnerships with local distributors and licensees in other regions. The company operates direct distribution in Australia, New Zealand, Singapore, Hong Kong, and South Africa, holds 70 percent stakes in its UK and European operations, and distributes select products in the US via licensees.
The company’s business model includes the AFT Direct division for core markets, AFT USA working with licensees, AFT EU partnering with European entities, and AFT ROW managing licensees and distributors in China, Japan, Korea, the Middle East, and North Africa. This multi-tiered approach enables effective management of diverse market dynamics and regulatory requirements while protecting brand integrity and intellectual property. The broad geographic reach provides resilience against regional fluctuations and multiple avenues for growth.
Robust R&D Pipeline with 8 Patented Products and Numerous Off-Patent Formulations
AFT maintains an active R&D pipeline comprising 8 patented products at various development stages, alongside over 24 off-patent injectable formulations under development or commercialisation. Currently, 7 R&D programmes are being commercialised across multiple countries, reflecting successful progression toward market launches. This diversified pipeline strategy supports sustained revenue growth by combining innovative patented therapies with improved off-patent formulations and alternative drug delivery methods addressing unmet needs.
Research efforts include new formulations, simpler over-the-counter variants, and significant IP projects such as a fridge-free formulation initiative aimed at expanding market access in regions with limited cold-chain infrastructure. Two major Australian over-the-counter dossiers are slated for filing by Q1 2027, pending successful clinical study completion, with each expected to target markets exceeding $50 million annually. These developments demonstrate AFT’s commitment to continuous innovation and addressing clinical and commercial gaps.
Nine Licensing Agreements Executed in FY26 to Support Growth
In FY26, AFT Pharmaceuticals completed 9 licensing agreements, reflecting an active strategy to broaden its product portfolio and market reach. These agreements include both in-licensing new products and intellectual property and out-licensing AFT products to distributors and partners internationally. The company’s extensive in-licensing operations support product development for affiliate markets and distribution through its global network, demonstrating a disciplined approach to portfolio expansion.
Licensing is a core growth pillar, enabling access to innovative therapies from external partners while maximizing the value of AFT’s own IP through strategic collaborations. This approach reduces R&D costs for certain products and accelerates market entry by leveraging partners’ local expertise and distribution channels. The consistent execution of multiple licensing deals annually highlights AFT’s ability to identify and secure valuable partnerships.
Innovative Migraine and Sinoject Projects Target Large Global Markets
AFT is developing new migraine formulations through an affiliate project with a 70 percent ownership stake, targeting $45 million in AFT affiliate markets and $180 million globally. The migraine project has advanced with additional dose forms developed, with commercial launches expected between Q4 2026 and Q1 2027. This initiative exemplifies AFT’s strategy of innovating existing active ingredients to meet clinical and commercial demands in high-potential therapeutic areas.
The AFT Sinoject project, also 70 percent owned by AFT, targets markets valued at approximately $700 million in affiliate regions and around $1.75 billion in European markets through AFT Pharma EU. These projects represent significant growth opportunities beyond AFT’s current portfolio and geography, underscoring the company’s diversified pipeline supporting sustained revenue and market expansion.
Australian Over-the-Counter Filings and Product Launch Plans
AFT is preparing to file two major Australian over-the-counter dossiers by the end of Q1 2027, contingent on successful clinical study completion. Each project is projected to exceed $50 million in sales potential, significantly enhancing AFT’s presence in the OTC pharmaceutical segment. These projects have completed clinical phases and are advancing toward regulatory submission and commercialisation.
Additional formulation developments, including new iron formulations and dose forms, are scheduled for launch between Q4 2026 and Q1 2027. These near-term commercial launches are expected to contribute meaningfully to FY27 revenue, aligning with AFT’s goal to reach $300 million in annual sales.
Pathway to $300 Million Revenue Supported by Multiple Growth Drivers
AFT Pharmaceuticals has set an ambitious $300 million annual revenue target, representing an 18 percent increase from FY26’s $254.7 million. This target reflects management’s confidence in growth driven by expansion in established markets, entry into new regions, commercialisation of pipeline products, and licensing partnerships. The company’s consistent revenue growth over two decades underpins optimism for achieving this milestone, with FY27 budgeted revenue aligned to this goal.
Growth drivers include sustained strong performance in Australia, rapid Asian market expansion including potential entries into Japan, commercial launches of R&D pipeline products in early 2027, expansion of European operations, and contributions from licensing collaborations in key international markets. AFT’s disciplined international expansion strategy emphasizes measured growth and operational excellence, supporting its evolution into a significant global pharmaceutical enterprise.
